Aminopeptidase · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Aminopeptidase shows clinical signal disease relevance led by acute myeloid leukemia. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P15144. Start with acute myeloid leukemia, then reuse UniProt P15144 as the stable protein anchor across project notes and exports.
Start with acute myeloid leukemia, then reuse UniProt P15144 as the stable protein anchor across project notes and exports.
Aminopeptidase shows clinical signal disease relevance led by acute myeloid leukemia. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with acute myeloid leukemia because it currently carries clinical signal support. Linked drugs include TOSEDOSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyAminopeptidase N
Review this target as Aminopeptidase, mapped to UniProt P15144. ChEMBL maps the protein component as Aminopeptidase N. Sequence length is 967 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Aminopeptidase as ChEMBL target CHEMBL3831223, mapped to UniProt P15144. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Aminopeptidase is the right protein anchor across sources, using UniProt P15144 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why acute myeloid leukemia is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Aminopeptidase |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | P15144 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Aminopeptidase N |
| UniProt Accession | P15144 |
| Component Type | Protein |
| Sequence Length | 967 aa |
Aminopeptidase N
Review this target as Aminopeptidase, mapped to UniProt P15144. ChEMBL maps the protein component as Aminopeptidase N. Sequence length is 967 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Aminopeptidase shows clinical signal disease relevance led by acute myeloid leukemia. 4 more disease programs remain visible in the same review block.
Start review with acute myeloid leukemia because it currently carries clinical signal support. Linked drugs include TOSEDOSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein format | 1 | 0 | — |